文献速递青光眼

英国选择性激光小梁成形术的真实世界疗效

Real-World Outcomes of Selective Laser Trabeculoplasty in the United Kingdom.
PubMed 文献 · Ophthalmology · 2019-11-26

这项回顾性观察研究分析了英国5个眼科教学中心831只接受首次选择性激光小梁成形术(SLT)的眼,评估其真实世界有效性与基线相关因素。结果显示术后12-18个月和24-36个月眼压显著下降但青光眼用药数显著增加,生存分析示6、12、24个月成功率分别为70%、45%、27%。基线眼压较高与治疗成功强相关,而年龄、基线视野平均偏差及合用降眼压药物与成功无关。

要点

  • SLT术后6、12、24个月治疗成功率分别为70%、45%、27%,多数患者在1年内失败。
  • 术后12-18个月眼压平均下降4.2 mmHg,24-36个月下降3.4 mmHg,但青光眼用药数显著增加。
  • 基线眼压>21 mmHg者治疗成功可能性更高(HR 0.67),年龄、视野缺损程度及合用降眼压药与成功无关。

核心结论

  • 多数患者对SLT初始有反应,但大多数在1年内治疗失败。
  • SLT疗效在基线眼压较高的患者中更好,但不因青光眼严重程度或合用降眼压药物而不同。

研究设计与样本

  • 回顾性观察研究,基于英国5个眼科教学中心的去标识电子病历(Medisoft青光眼模块)。
  • 纳入接受首次记录的SLT的成人患者,双眼同日SLT者随机选1眼分析,共分析831例患者的831只眼。
  • 采用多变量Cox回归评估与治疗成功相关的因素,并进行Kaplan-Meier生存分析。

主要发现

  • 术后12-18个月眼压平均下降4.2 mmHg(95%CI -4.7至-3.7,P<0.0001),24-36个月下降3.4 mmHg(95%CI -4.1至-2.7,P<0.0001)。
  • 术后12-18个月青光眼用药数平均增加0.13(95%CI 0.04-0.23,P=0.007),24-36个月增加0.20(95%CI 0.06-0.33,P=0.005)。
  • 生存分析示SLT术后6、12、24个月治疗成功率分别为70%、45%、27%。
  • 基线眼压>21 mmHg相较于≤21 mmHg与治疗成功强相关(HR 0.67,95%CI 0.57-0.80,P<0.001)。
  • SLT成功与年龄(P=0.78)、基线视野平均偏差(P=1.00)或合用降眼压药物(P=0.52)无显著关联。

关键数值与推荐

  • SLT失败定义为术后接受任何进一步青光眼手术,或连续两次随访出现以下任一:眼压>21 mmHg、眼压较基线下降<20%、青光眼用药较基线增加。
  • 主要结局指标为术后12-18个月和24-36个月眼压及青光眼用药数较基线的变化。

临床怎么用

  • 基线眼压较高的患者可能更适合接受SLT治疗。
  • 应告知患者SLT多数在1年内失效,需规划后续治疗或监测。
  • 青光眼严重程度及是否合用降眼压药物不应作为选择SLT的限制因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Selective laser trabeculoplasty (SLT) is a common treatment option for managing glaucoma and ocular hypertension. We assessed the real-world effectiveness of SLT and baseline factors associated with treatment success in the United Kingdom. DESIGN: Retrospective observational study of de-identified electronic medical records (Medisoft Glaucoma module [Medisoft Ltd, Leeds, UK]) from 5 UK ophthalmology teaching centers. PARTICIPANTS: Adult patients undergoing their first recorded SLT. For bilateral SLT (same day), analyses included 1 randomly selected eye. METHODS: Patient demographics, procedure details, and clinical outcomes data were extracted. Factors associated with treatment success were assessed using multivariable Cox regression. MAIN OUTCOME MEASURES: Change from baseline in intraocular pressure (IOP) and glaucoma medication use at 12 to 18 and 24 to 36 months post-SLT. A Kaplan-Meier survival analysis was also conducted. Failure of SLT was defined as any further glaucoma procedure post-SLT or any of the following at 2 consecutive visits: IOP >21 mmHg, IOP reduction <20% from baseline, or increase in glaucoma medications from baseline. RESULTS: A total of 831 SLT-treated eyes (mean baseline IOP 22.0 mmHg) of 831 patients were analyzed. At 12 to 18 and 24 to 36 months post-SLT, respectively, significant reductions in IOP (-4.2 [95% confidence interval {CI}, -4.7 to -3.7] and -3.4 [95% CI, -4.1 to -2.7] mmHg; both P < 0.0001) and significant increases in the number of glaucoma medications (0.13 [95% CI, 0.04-0.23], P = 0.007, and 0.20 [95% CI, 0.06-0.33], P = 0.005) were observed. Survival analysis demonstrated treatment success in 70%, 45%, and 27% of eyes at 6, 12, and 24 months post-SLT, respectively. Higher baseline IOP was strongly associated with treatment success (hazard ratio [HR], 0.67 for baseline IOP >21 mmHg vs. ≤21 mmHg, 95% CI, 0.57-0.80; P < 0.001). Selective laser trabeculoplasty success was not significantly associated with age (P = 0.78), baseline visual field mean deviation (P = 1.00), or concurrent use of IOP-lowering medication (P = 0.52). CONCLUSIONS: Most patients initially responded to SLT, but the majority failed within 1 year. Efficacy of SLT was better in patients with higher baseline IOP but did not differ by glaucoma severity or concurrent use of IOP-lowering medication. These findings may help inform which patients are suitable for SLT therapy.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Khawaja AP, Campbell JH, Kirby N, et al. Real-World Outcomes of Selective Laser Trabeculoplasty in the United Kingdom. Ophthalmology. 2019. PMID: 31952882. doi:10.1016/j.ophtha.2019.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。